$ANEB News
Last published 9mo ago
- 9mo agoANEBAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today
- 9mo agoANEBAnebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SECBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today
- 9mo agoANEBAnebulo Pharmaceuticals Announces Final Results of Tender OfferBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today
- 10mo agoANEBAnebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender OfferBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today
- 12mo agoANEBAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today
- 1y agoANEBAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc.
- 1y agoANEBAnebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced ToxicityBusiness WireAnebulo Pharmaceuticals, Inc.
- 1y agoANEBAnebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic AlternativesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today
- 1y agoANEBAnebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common StockBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today
- 1y agoANEBAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today
- 1y agoANEBAnebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital RaiseBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today
- 1y agoANEBAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today
- 2y agoANEBAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today
- 2y agoANEBAnebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic EffectsBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), has been
- 2y agoANEBLFCRLGNDQLGNLifecore Biomedical Announces Cooperation Agreement with 22NWGlobeNewswireCHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced
- 2y agoANEBAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI)
- 2y agoANEBAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the "Company" or
- 2y agoANEBAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the "Company" or
- 3y agoAMGNANEBJAZZLGND+4Ligand Reports Third Quarter 2023 Financial ResultsBusiness WireRaising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today
- 3y agoANEBAnebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the
- 3y agoANEBAnebulo Pharmaceuticals Announces New CEOBusiness WireRichie Cunningham announced as Chief Executive Officer and member of Anebulo's board of directors Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) ("Anebulo"), a clinical-stage biopharmaceutical company
- 3y agoANEBAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the "Company" or
- 3y agoANEBAnebulo Pharmaceuticals to Present at Upcoming Investor and Scientific ConferencesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the "Company" or
- 3y agoANEBAnebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 ExtensionBusiness WireFDA provides favorable input on studies to support ANEB-001 approval Part C Extension of Phase 2 trial completed exploring THC challenge dose of up to 60 mg Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) (the "Company"
- 3y agoANEBDLHCHBIOHOOK+15Sidoti Events, LLC's Virtual August Micro-Cap ConferenceACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place
- 3y agoANEBAnebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent UpdatesPR NewswireAUSTIN, Texas, May 11, 2023 /PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication
- 3y agoANEBLGNDNOVNNVS+2Ligand Reports First Quarter 2023 Financial ResultsBusiness Wire2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and
- 3y agoANEBAnebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid IntoxicationPR NewswireANEB-001 statistically significantly reduced VAS Feeling High in all cohorts (p=<0.0001 at the 30 mg THC dose level)A single 10 mg oral dose of ANEB-001 reduced key symptoms of Accute Cannabinoid Intoxication induced
- 3y agoANEBAnebulo Pharmaceuticals Expands its Integrated and Outsourced SolutionsPR NewswireAdditional operational efficiencies and opportunities expected with the engagement of Potrero Hill AdvisorsSandra Gardiner succeeds Rex Merchant as acting chief financial officerAUSTIN, Texas, March 8, 2023 /PRNewswire/
- 3y agoAAONABMACAAFIB+25Sidoti & Company, LLC Announces Registration Now Open for March Small-Cap and May Micro-Cap ConferencesACCESS NewswireNEW YORK, NY / ACCESSWIRE / February 14, 2023 / Sidoti & Company, LLC announces that its two spring conferences are now open for registration. The March Virtual Small-Cap Conference will take place on Wednesday and
- 3y agoANEBAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the "Company" or
- 3y agoANEBAnebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid IntoxicationBusiness WirePreliminary data showed ANEB-001 reduced effects of a 30 mg dose of THC Delayed dosing of ANEB-001 rapidly reversed pre-existing THC effects Full PK, PD, and safety data expected by end of 1Q2023 Company
- 4y agoANEBAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the "Company" or
- 4y agoANEBAnebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of DirectorsBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the
- 4y agoANEBAnebulo Pharmaceuticals Announces $6.6 Million Private Placement FinancingBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction (the "Company" or "Anebulo"), today announced that
- 4y agoANEBAnebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid IntoxicationBusiness WireLower doses of ANEB-001 reduced the negative effects of higher doses of THC Currently exploring delayed dosing to better understand real-world conditions Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company
- 4y agoANEBAnebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022Business WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), will host its in
- 4y agoANEBAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business ProgressBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the "Company" or "Anebulo"), today announced financial resul
- 4y agoANEBAnebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26Business WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), will host its in
- 4y agoAIRIANEBAPRNARC+25Sidoti's August Micro-Cap Virtual ConferenceACCESS NewswirePresentation Times and Weblinks Released for Over 50 Presenting Companies Wednesday and Thursday, August 17-18, 2022 NEW YORK, NY / ACCESSWIRE / August 16, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-d
- 4y agoANEBAnebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid IntoxicationBusiness WireStudy Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-
- 4y agoANEBAnebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022Business WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), anticipates rele
- 4y agoANEBAnebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific OfficerBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), today announced
- 4y agoANEBAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the "Company" or "Anebulo"), today announced financial resul
- 4y agoANEBAnebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND SubmissionBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), today announced
- 4y agoANEBAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent UpdatesBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the "Company" or "Anebulo"), today announced financial resul
- 4y agoANEBAnebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual ConferenceBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at
- 4y agoANEBAnebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public RelationsBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. Anderson as H
- 4y agoAMAMANEBAnebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and DirectorBusiness WireAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a membe
- 4y agoANEBAnebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid IntoxicationBusiness WireAffirms expectations for initial topline results in 1H 2022 Recent FDA pre-IND meeting provides valuable guidance on U.S. regulatory path; company expects to submit IND in 1Q 2022 Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage bioph